Clinical Trials
11 trialsNCT03325101 2025-06-12
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
Phase 1/2 Terminated
NCT01045460 2021-04-09
aMILs
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01329900 2020-07-08
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00651937 2020-01-14
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT01174082 2018-06-01
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02433483 2017-11-01
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT00733824 2017-03-09
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Washington University School of Medicine
Phase 1/2 Completed
NCT00499343 2013-08-02
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00499889 2012-04-23
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Phase 2 Terminated